Submit to Special Issue Submit Abstract to Special Issue Review for Uro Propose a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Special Issue "Andrology and Reproductive Health"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Published Papers

A special issue of Uro (ISSN 2673-4397).

Deadline for manuscript submissions: 31 December 2023 | Viewed by 2234

Share This Special Issue

Special Issue Editor

Prof. Dr. Tommaso Cai

E-Mail Website
Guest Editor

Department of Urology, Santa Chiara Regional and Teaching Hospital, 38123 Trento, Italy
Interests: andrology; biofilm; bladder cancer; bph; functional urology; nutraceuticals and phytotherapy; prostate cancer; penile cancer; urinary tract infections; mini-invasive surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Several decades ago, it was almost impossible to even imagine the progress that we have seen today in andrology and reproductive health. As you well know, the modern history of andrology is strictly associated to the discovery of sildenafil. Since March 1998, when sildenafil became available in the United States, we have had new PDE5-is drugs, and the amount of research has increased in the andrological field. Technical innovations, new drugs, and new insights in the pathophysiology of andrological disease have also improved our knowledge in the field of reproductive health. With respect to andrology and reproductive health, we have recently taken a giant step forward, but there are some grey zones: developing new diagnostic tools, new management strategies in infertile men, and the influence of factors on semen quality such as air pollution, the use of pesticides, and harmful chemicals. Evidently, andrology and reproductive health are rapidly evolving sciences. In this Special Issue, we wish to discuss the newest findings concerning the grey zones in andrology and reproductive health, giving readers useful tools for everyday clinical practice. Key areas of this Special Issue include but are not limited to andrology, erectile dysfunction, precox ejaculation, hormone stimulation, hypogonadism, male infertility, testicular sperm extraction, and varicocele. Moreover, special attention will be given to the psychological impact of andrological diseases and the role of partners. We hope to give readers an interesting and multidisciplinary tool for use in everyday clinical practice and to invite many colleagues to focus part of their clinical research in the field of andrology and reproductive health.

Prof. Dr. Tommaso Cai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Uro is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle

Efficacy and Safety of a Natural Supplement Containing Serenoa Repens, Solanum Lycopersicum, Lycopene, and Bromelain in Reducing Symptoms of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Cohort Study in 250 Patients

Antonio Andrea Grosso

and

Uro 2023, 3(3), 199-207; https://doi.org/10.3390/uro3030021 - 20 Jul 2023

Viewed by 385

Abstract

Background: Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III is a widespread condition affecting men universally, with existing treatments showing limited success. This study evaluated the efficacy and safety of a natural supplement, composed of Serenoa repens, Solanum lycopersicum, lycopene, and bromelain, in managing symptoms of this condition among a substantial patient group. Methods: In this prospective study, 245 patients diagnosed with Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III were treated with the aforementioned supplement, alongside lifestyle alterations, such as refraining from spicy foods, alcohol, caffeine, and cycling, for a duration of three months. Patients’ progress was assessed at one and three months using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Index (IPSS), quality of life (QoL) scores, and changes in total prostate-specific antigen (PSA) levels. Results: The supplement was well received with no serious adverse events reported. Significant improvements were observed in NIH-CPSI scores, IPSS, QoL scores, and a substantial decrease in total PSA levels at three months compared to baseline, with a positive trend noted from one-month to three-month evaluations. This was consistent in either patients with predominantly voiding or storage urinary symptoms. Conclusions: Our results suggest that this natural supplement in conjunction with lifestyle changes could offer a safe and effective alternative treatment for patients suffering from Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III. However, these findings require validation through further large-scale randomized controlled trials. Full article

(This article belongs to the Special Issue Andrology and Reproductive Health)

► Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview

Effectiveness of Silymarin, Sulforaphane, Lycopene, Green Tea, Tryptophan, Glutathione, and Escin on Human Health: A Narrative Review

and

Uro 2023, 3(3), 208-228; https://doi.org/10.3390/uro3030022 - 09 Aug 2023

Viewed by 448

Abstract

Background: Recently, the role of nutraceutical compounds in the prevention of human diseases has been rapidly increasing. Here, we aim to evaluate the beneficial effect of dietary supplementation with seven active principles, i.e., lycopene, sulforaphane, silymarin, glutathione, escin, tryptophan, and green tea catechins, on human health. Methods: An extensive search of PubMed and Medline database was performed with the following keywords: “silymarin”, “sulforaphane”, “lycopene”, “green tea catechins”, “tryptophan”, “glutathione” and “escin” accompanied by the keywords “supplement”, “supplementation”, and “nutraceutics”. All preclinical and clinical trials were considered for this review. Results: One hundred and eighteen full-text articles were eligible for inclusion in this review. The papers examined presented considerable variability due to the wide heterogeneity of dosages administered, population involved, and outcomes pursued. Conclusion: Nutritional supplementation with lycopene, sulforaphane, silymarin, glutathione, escin, tryptophan, and green tea catechins appears to exert a wide range of benefits on human health, ranging from mood and cognition to cardiovascular health, fertility, metabolism, antioxidant, and anti-inflammatory capabilities, as well as potential anticancer effects. Further studies are required to better define the potential synergic effect, optimal dosage, mechanism of action, and tolerability profiles of these substances. Full article

(This article belongs to the Special Issue Andrology and Reproductive Health)

► Show Figures

Figure 1

Open AccessReview

Current Evidence on the Use of Hyaluronic Acid as Nonsurgical Option for the Treatment of Peyronie’s Disease: A Contemporary Review

Marco Capece

Giuseppe Celentano

and

Roberto La Rocca

Uro 2023, 3(2), 160-167; https://doi.org/10.3390/uro3020017 - 01 Jun 2023

Viewed by 1147

Abstract

Peyronie’s disease is a condition characterized by the formation of fibrous plaques in the tunica albuginea, which can cause pain, curvature, and erectile dysfunction. Preclinical studies have demonstrated the potential benefits of hyaluronic acid in treating Peyronie’s disease, including antifibrotic, anti-inflammatory, and proangiogenic effects, although more research is needed to fully understand its mechanisms of action. Clinical studies have shown promising results, with hyaluronic acid injections leading to improvements in plaque size, penile curvature, and erectile function, and being well tolerated by patients. The findings suggest that HA injections could be a viable and safe treatment option for Peyronie’s disease, particularly in the early stages of the disease. However, more research is needed to determine the optimal dosage and treatment duration for HA injections, and to confirm its efficacy in the stable phase of Peyronie’s disease. Overall, hyaluronic acid is a potentially effective therapy for Peyronie’s disease, with the ability to inhibit fibrosis and promote angiogenesis, and low risk of adverse effects, making it an attractive option for patients who are unable or unwilling to undergo surgery. Full article

Journal Menu

Journal Browser

Special Issue "Andrology and Reproductive Health"

Share This Special Issue

Special Issue Editor

Special Issue Information

Published Papers (3 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI